HCA - HCA Healthcare, Inc. Stock Analysis | Stock Taper
Logo
HCA Healthcare, Inc.

HCA

HCA Healthcare, Inc. NYSE
$378.54 -1.52% (-5.85)

Market Cap $83.98 B
52w High $556.52
52w Low $330.00
Dividend Yield 0.61%
Frequency Quarterly
P/E 13.04
Volume 2.35M
Outstanding Shares 221.84M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q1-2026 $19.11B $0 $1.62B 8.48% $7.15 $3.79B
Q4-2025 $19.51B $5B $1.88B 9.62% $8.14 $4.16B
Q3-2025 $19.16B $5.05B $1.64B 8.57% $7.05 $3.87B
Q2-2025 $18.61B $4.66B $1.65B 8.88% $6.91 $3.85B
Q1-2025 $18.32B $4.71B $1.61B 8.79% $6.52 $3.73B

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q1-2026 $940M $61.45B $64.43B $-6.3B
Q4-2025 $1.04B $60.72B $63.49B $-6.03B
Q3-2025 $997M $59.75B $61.91B $-5.33B
Q2-2025 $1.04B $59.54B $60.77B $-4.39B
Q1-2025 $1.06B $59.8B $60.24B $-3.52B

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q1-2026 $1.62B $2.01B $-1.28B $-830M $-100M $895M
Q4-2025 $1.88B $2.36B $-1.32B $-999M $43M $870M
Q3-2025 $1.64B $4.42B $-1.39B $-2.97B $58M $3.13B
Q2-2025 $1.89B $4.21B $-1.25B $-3.09B $-121M $3.03B
Q1-2025 $1.82B $1.65B $-1.03B $-1.5B $-873M $660M

Revenue by Products

Product Q2-2025Q3-2025Q4-2025Q1-2026
International
International
$460.00M $480.00M $470.00M $500.00M
Managed Care And Other Insurers
Managed Care And Other Insurers
$9.12Bn $9.27Bn $9.54Bn $9.08Bn
Managed Medicaid
Managed Medicaid
$900.00M $950.00M $970.00M $940.00M
Managed Medicare
Managed Medicare
$3.35Bn $3.31Bn $3.48Bn $3.51Bn
Medicaid
Medicaid
$1.44Bn $1.78Bn $1.50Bn $1.44Bn
Medicare
Medicare
$2.80Bn $2.73Bn $2.85Bn $3.06Bn

Revenue by Geography

Region Q2-2025Q3-2025Q4-2025Q1-2026
American Group
American Group
$6.49Bn $6.69Bn $6.93Bn $6.57Bn
Atlantic Group
Atlantic Group
$6.12Bn $6.14Bn $6.28Bn $6.36Bn
National Group
National Group
$5.20Bn $5.53Bn $5.49Bn $5.32Bn

Q1 2026 Earnings Call Summary

Read Call Summary

5-Year Trend Analysis

A comprehensive look at HCA Healthcare, Inc.'s financial evolution and strategic trajectory over the past five years.

+ Strengths

HCA combines accelerating revenue growth with improving profitability and strong cash generation. Its scale and dense network across many markets give it significant negotiating power and operating leverage. The company has a clear edge in data and analytics, reinforced by proprietary AI‑driven tools and a strategic partnership with Google Cloud. Ownership of Galen College of Nursing offers a unique solution to labor constraints, and rising free cash flow supports both substantial reinvestment in facilities and technology and meaningful returns of capital to shareholders.

! Risks

The main financial risks center on leverage and liquidity. Debt levels and net debt have increased steadily, while shareholders’ equity has turned negative and retained earnings have been drawn down by heavy capital returns, leaving less of a balance‑sheet cushion. Liquidity ratios remain tight, so the company depends heavily on continued strong cash generation and access to capital markets. Operationally, HCA must navigate industry‑wide challenges such as labor shortages, wage pressures, regulatory uncertainty, and competition from both large systems and specialized providers. There is also execution risk around scaling complex technology and AI initiatives across such a large organization.

Outlook

Based on the provided information, HCA appears to be a fundamentally strong operator with an improving income statement, robust cash flows, and a sophisticated innovation agenda, but with a more aggressive balance‑sheet posture than many peers. If management continues to translate its scale, technology investments, and nursing pipeline into better margins and cash flow, the company is well positioned to benefit from growing healthcare demand and the shift toward data‑driven care. However, the combination of high leverage, tight liquidity, and sector headwinds means that the forward path is not without risk, and future performance will hinge on disciplined capital allocation and successful execution of its operational and technology strategies.